What is GoodRx?
Prescription savings and consumer healthcare marketplace company with $796.9M 2025 revenue; $194.0M Q1 2026 revenue scale.
- Category
- Prescription savings and consumer healthcare marketplace
- Headquarters
- Santa Monica, CA
- Founded
- 2011
- Employees
- 700+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: GDRX
What is GoodRx?
GoodRx is a Prescription savings and consumer healthcare marketplace company headquartered in Santa Monica, CA. As of June 2026, its clearest scale signal is $796.9M 2025 revenue; $194.0M Q1 2026 revenue.
GoodRx operates a consumer prescription-savings, pharma manufacturer-solutions, subscription, and telehealth marketplace used by U.S. consumers and pharmacies. Its core customer set includes consumers, pharmacies, pharmacy benefit managers, pharmaceutical manufacturers, advertisers, and telehealth patients, and its public product surface includes Prescription coupons, GoodRx Gold, Manufacturer affordability programs, GoodRx Care, Pharma direct solutions. The current scale signal is $796.9M 2025 revenue; $194.0M Q1 2026 revenue, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does GoodRx offer?
GoodRx offers Prescription coupons, GoodRx Gold, Manufacturer affordability programs, GoodRx Care and related healthcare workflows.
- Prescription coupons· Core product
- GoodRx Gold· Core product
- Manufacturer affordability programs· Core product
- GoodRx Care· Workflow
- Pharma direct solutions· Workflow
- Drug-price transparency· Workflow
- Provider mode· Platform
- Mobile app· Platform
How does GoodRx make money?
GoodRx earns transaction revenue from prescription savings, subscriptions, manufacturer-solutions revenue, telehealth, and advertising or other consumer-health services.
GoodRx earns transaction revenue from prescription savings, subscriptions, manufacturer-solutions revenue, telehealth, and advertising or other consumer-health services. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Consumer coupon use is free; GoodRx Gold is a paid subscription, while manufacturer and advertising programs are contracted by campaign, medication, audience, pharmacy reach, and performance. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads GoodRx?
GoodRx is led by Wendy Barnes, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Wendy BarnesPresident and Chief Executive OfficerCEO since 2024Leads the consumer affordability and manufacturer-solutions strategy.
- Karsten VoermannChief Financial OfficerCFOOwns finance, investor relations, and capital allocation.
- Scott WagnerDirector and former interim CEOBoard leaderFormer executive leader during the company's operating reset.
- Trevor BezdekCo-founder and ChairmanCo-founderCo-founded GoodRx and remains a key board-level company builder.
How do you contact GoodRx's leadership?
GoodRx publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
investors@goodrx.com (official published/company IR contact); personal executive format not verifiedHow much funding has GoodRx raised?
GoodRx is a public company (Nasdaq: GDRX), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2011: Founded - GoodRx launches around prescription price comparison and coupons. 2018: Silver Lake investment - Private-equity growth investment supports scale before the IPO. 2020: IPO - GoodRx lists on Nasdaq under GDRX. 2025: Full-year results - GoodRx reports $796.9M of 2025 revenue. 2026: Q1 update - GoodRx reports $194.0M of first-quarter 2026 revenue.
As of June 2026, GoodRx's practical funding capacity is best read through Nasdaq: GDRX, $796.9M 2025 revenue; $194.0M Q1 2026 revenue, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives GoodRx access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did GoodRx get here?
GoodRx grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2011Company foundedGoodRx begins aggregating prescription prices for consumers.
- 2017Subscription expansionGoodRx Gold adds recurring consumer subscription economics.
- 2020Nasdaq listingGoodRx becomes a public company.
- 2023Manufacturer-solutions expansionPharma direct affordability programs become a larger growth vector.
- 2025Revenue mix shiftPharma direct grows while prescription transaction revenue resets.
- 2026Oral GLP-1 access programGoodRx expands affordability programs for diabetes and weight-management medication access.
Who are GoodRx's competitors?
GoodRx competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- SingleCarePrescription savings card and consumer pharmacy-discount competitor.
- Amazon PharmacyConsumer pharmacy and Prime-integrated prescription pricing competitor.
- Mark Cuban Cost Plus DrugsTransparent-price online pharmacy competitor.
- Blink HealthPrescription price and fulfillment marketplace competitor.
- Optum PerksUnitedHealth-owned prescription discount and pharmacy-benefits offering.
- RxSaverCoupon and price-comparison competitor.
GoodRx — frequently asked questions
